Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Dietary Supplement: meal intake; Dietary Supplement: Placebo

• Registration Number: NCT01727583
• Lead Sponsor: Société des Produits Nestlé (SPN)

Brief Summary

This pilot study is aimed at assessing the acute effect of several combinations of lipids differing in their fatty acid composition on glucagon-like-peptide (GLP)-2 and GLP-1 secretion in healthy subjects.

Detailed Description

In this study, the investigators aim to investigate the effect of various lipid types on GLP-2 and GLP-1 secretion. This will allow to determine the importance of lipids in nutritional solutions. Moreover, this will allow us to assess whether existing clinical formulas can be improved in order to stimulate GLP-2 and accelerate intestinal recovery.

Study Timeline

• Study Start: 2012-09
• Study First Submitted: 2012-11-12
• Study First Submitted QC: 2012-11-15
• Study First Posted: 2012-11-16
• Primary Completion: 2013-10
• Status Verified: 2013-11
• Study Completion: 2013-11
• Last Update Submitted: 2013-11-07
• Last Update Posted: 2013-11-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 18

Inclusion Criteria

• BMI : 19 - 24.9 kg.m-2
• Normal fasting glycemia
• Having obtained his informed consent.

Exclusion Criteria

• Gastro-intestinal disease (ulcer), pancreatic disease, hepatic disease, metabolic diseases / disorders (diabetes, dyslipidemia), renal disease, cardiovascular disease (arterial hypertension), as determined by the medical screening visit and a blood analysis.
• Have had a gastrointestinal surgery (with the exception of appendices resection).
• Malabsorption disorders
• Lactose intolerance
• Significant weight loss during the past three months (more than 5% of initial weight)
• Have a regular consumption of medication
• Regular supplements (vitamins and minerals) intake during the previous month
• Have an alcohol intake: > 2 units a day
• Smoker (more than 2 cigarettes a day)
• Illicit substances intake, as stated on the medical screening questionnaire
• Allergy to any food or medication
• Anaemia defined by a number of erythrocytes or hemoglobin Hb or hematocrit Ht which are inferior to laboratory normal ranges
• Having given blood in the past three months or willing to give blood in the 3 months following the completion of the study
• Intense physical activity > 3 hours per week
• Currently participating or having participated in another clinical trial during the past month.
• Volunteer who cannot be expected to comply with the protocol, including consuming rapidly the study products, chronic medication intake

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Lipid 1	meal intake	Meal intake
Lipid-free	Placebo	Maltodextrine + proteins
Lipid 2	meal intake	Meal intake
Lipid 3	meal intake	Meal intake
Lipid 4	meal intake	meal intake

Primary Outcome Measures

Name	Time	Method
GLP-2 and GLP-1 kinetics	changes from baseline to 4 hours following meal intake	GLP-2 and GLP-1 are measured using Elisa

Secondary Outcome Measures

Name	Time	Method
Intestinal and metabolic hormones	Changes from baseline to 4 hours following meal intake	Those hormones will be measured based on enzymatic technics

Trial Locations

Locations (1)

Nestlé CDU / Metabolic Unit; 🇨🇭 Lausanne, Switzerland